SK pharmteco specializes in the commercial and clinical production of APIs, Advanced Intermediates, Gene Therapies, Registered Starting Materials and Key Building Blocks. Our offerings include process R&D, analytical method development and stability, scale-up and optimization, validation and commercial production of small molecules as well as extensive Adeno-Associated Virus (AAV) and Lentiviral vector development and cGMP production capabilities.

Our global operations include eight cGMP manufacturing, development and analytical facilities across the US, Korea, Ireland and France.

We have a strong record of environmental, health, and safety performance. All our plants have been successfully audited by global regulatory agencies including the FDA (US), EMA (Europe), PMDA (Japan), and MFDS (Korea).

Extensive technology toolbox and ~1,000 m³ of global small-molecule capacity plus 5,000 m² of large molecule facilities.

SK pharmteco is a leader in operational excellence and continuous improvement. Our highly skilled team delivers innovative solutions across the following offerings:
- Continuous Flow Processing
- Chromatography: SMB & Batch
- High Potency (Up to 4 m³ scale & down to 10 ng/m³ containment)
- Energetic Chemistry
- Controlled Substances (US DEA Schedule II-V Manufacturing)
- Particle Engineering
- cGMP Manufacturing in Adherent & Suspension Systems for Viral Vectors (AAV, LVV)